Life Science

Inventory level rising quickly throughout the supply chain due to disruption, yet many items still always out of stock. Hard to identity the root cause and take actions on inventory level.

Difficulty in assessing the impact on the end-to-end supply chain from changing regulatory requirements.

Expectation of continuing extreme demand volatility even in the post-pandemic era.

Increasing of Spin-off (consumer/OTC business division) and M&A (in Biotech and Rx side of business) create further challenges to the supply chain operation